Fan Die, Hu Jilei, Lin Ning
Clinical Nutrition, The General Hospital of Western Theater Command, Chengdu, China.
Front Nutr. 2025 Apr 25;12:1586129. doi: 10.3389/fnut.2025.1586129. eCollection 2025.
Pediatric asthma, a prevalent chronic disease with rising global incidence, imposing substantial healthcare and socioeconomic burdens. Emerging evidence highlights the gut-lung axis as a pivotal therapeutic target, with microbiota dysbiosis implicated in immune dysregulation and airway hyperresponsiveness. This systematic review evaluated the efficacy and safety of probiotics, prebiotics, synbiotics, and postbiotics in pediatric asthma management.
A comprehensive search of PubMed, Cochrane library, Web of Science, and Embase was conducted up to 2nd January 2025. Inclusion criteria encompassed randomized controlled trials (RCTs) evaluating the therapeutic use of probiotics, prebiotics, synbiotics, or postbiotics in children and/or adolescents (<18 years) with asthma.
Eighteen studies (13 RCTs, = 2,419 participants) were analyzed, focusing on children aged < 18 years. Probiotic interventions, predominantly (5 studies) and (5 studies), demonstrated significant reductions in asthma exacerbations and improved pulmonary function, with strain-specific effects linked to Th2 cytokine suppression and gut-lung axis modulation. Postbiotics, including bacterial lysates (OM-85 BV, PMBL), attenuated airway hyperresponsiveness and systemic inflammation. Synbiotics reduced viral respiratory infections and healthcare utilization. However, there is still a lack of direct RCTs to explore the therapeutic effects of prebiotics on pediatric asthma. Key limitations include methodological heterogeneity (dosing: 10-10 CFU/day; duration: 8 weeks-12 months) and risk of bias (3 low-risk, 12 with concerns).
Our findings underscored the potential of microbiota-targeted therapies but highlight the need for standardized protocols, strain-specific trials, and pediatric prebiotic research. Future studies should integrate multi-omics to elucidate mechanisms and optimize personalized interventions.
https://www.crd.york.ac.uk/PROSPERO/view/CRD42025641318, identifier: CRD42025641318.
儿童哮喘是一种全球发病率不断上升的常见慢性疾病,给医疗保健和社会经济带来了沉重负担。新出现的证据表明,肠-肺轴是一个关键的治疗靶点,微生物群失调与免疫失调和气道高反应性有关。本系统评价评估了益生菌、益生元、合生元和后生元在儿童哮喘管理中的疗效和安全性。
截至2025年1月2日,对PubMed、Cochrane图书馆、Web of Science和Embase进行了全面检索。纳入标准包括评估益生菌、益生元、合生元或后生元在儿童和/或青少年(<18岁)哮喘患者中治疗用途的随机对照试验(RCT)。
分析了18项研究(13项RCT,n = 2419名参与者),重点关注年龄<18岁的儿童。益生菌干预,主要是嗜酸乳杆菌(5项研究)和双歧杆菌(5项研究),显示哮喘发作显著减少,肺功能改善,菌株特异性效应与Th2细胞因子抑制和肠-肺轴调节有关。后生元,包括细菌裂解物(OM-85 BV、PMBL),减轻了气道高反应性和全身炎症。合生元减少了病毒性呼吸道感染和医疗保健利用。然而,仍然缺乏直接的RCT来探索益生元对儿童哮喘的治疗效果。主要局限性包括方法学异质性(剂量:10^6-10^11 CFU/天;持续时间:8周-12个月)和偏倚风险(3项低风险,12项有担忧)。
我们的研究结果强调了以微生物群为靶点的治疗方法的潜力,但也突出了对标准化方案、菌株特异性试验和儿童益生元研究的需求。未来的研究应整合多组学技术,以阐明机制并优化个性化干预措施。
https://www.crd.york.ac.uk/PROSPERO/view/CRD42025641318,标识符:CRD42025641318。